Jeffrey L Garwin

This inventor holds 10 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Biomoda, Inc., Bioaffinity Technologies, Inc., Mcneil-Ppc, Inc.. Active years: 1993-2016.

USPTO Granted Patents = 10

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 2

Average Co-Inventor Count = 1.0

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

Paoli, PA (US) (1993 - 1997)
Wayne, PA (US) (2005)
Chapel Hill, NC (US) (2008 - 2016)

Company Filing History:

Bioaffinity Technologies, Inc.

Years Active: 1993-2016

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9417241 - 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP) and kit for use with detecting cancer (2016-08-16),

2. 8975038 - Method for determining presence of carcinomic cells with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2015-03-10),

3. 8486656 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2013-07-16),

4. 7960138 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2011-06-14),

5. 7670799 - Method for making 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP) solution and composition comprising TCPP (2010-03-02),

6. 7384764 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2008-06-10),

7. 6838248 - Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2005-01-04),

8. 5612054 - Pharmaceutical compositions for treating gastrointestinal distress (1997-03-18),

9. 5248505 - Method for treating gastrointestinal distress (1993-09-28),

10. 5246717 - Eggs compatible with cholesterol-reducing diet and method of producing (1993-09-21),

Title: Innovations in Cancer Detection by Jeffrey L. Garwin

Introduction

Jeffrey L. Garwin is a notable inventor based in Wayne, PA, who has made significant contributions to the field of cancer detection. With a total of seven patents to his name, Garwin's work focuses on innovative methods and kits that enhance the prognosis of cancer therapies.

Latest Patents

Among his latest patents are the development of 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP) and a kit designed for detecting cancer. This kit contains TCPP, which is utilized to prognose a patient's response to cancer therapy. The process involves contacting a sample of cells from the patient's tissue with a solution of TCPP, allowing it to bind to any abnormal dysplastic or carcinomic cells present. The detection of TCPP fluorescence in the sample indicates the presence of these cells. Furthermore, the method includes performing similar tests on additional samples during and after therapy to determine if the percentage of abnormal pre-cancerous cells has decreased, which would suggest a positive response to the treatment.

Career Highlights

Garwin has worked with several companies, including Biomoda, Inc. and Bioaffinity Technologies, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions for cancer detection.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Jeffrey L. Garwin's innovative work in cancer detection through the use of TCPP represents a significant advancement in the field, providing valuable tools for improving patient outcomes. His contributions continue to influence cancer therapy prognosis and detection methodologies.